Cargando…

Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation

BACKGROUND: Despite the increasing use of adjuvant bisphosphonates for early stage breast cancer (EBC), little is known about the patient experience with such treatments. A patient survey was performed to identify current prescribing practices, perceptions around the role of treatment, the impact of...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGee, Sharon, AlZahrani, Mashari, Stober, Carol, Ng, Terry L., Cole, Katherine, Larocque, Gail, Awan, Arif, Sehdev, Sandeep, Hilton, John, Vandermeer, Lisa, Hutton, Brian, Pond, Gregory, Saunders, Deanna, Clemons, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930351/ https://www.ncbi.nlm.nih.gov/pubmed/33680749 http://dx.doi.org/10.1016/j.jbo.2021.100351

Ejemplares similares

Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey
por: McGee, Sharon, et al.
Publicado: (2021)

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
por: AlZahrani, Mashari, et al.
Publicado: (2020)

Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
por: Alzahrani, Mashari, et al.
Publicado: (2021)

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer
por: Dent, Susan, et al.
Publicado: (2021)

The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design
por: Saunders, Deanna, et al.
Publicado: (2021)

Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers
por: Cole, Katherine Marie, et al.
Publicado: (2021)

Vasomotor symptoms in early breast cancer—a “real world” exploration of the patient experience
por: Cole, Katherine Marie, et al.
Publicado: (2022)

Using machine learning to predict individual patient toxicities from cancer treatments
por: Cole, Katherine Marie, et al.
Publicado: (2022)

The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer
por: Surujballi, Julian, et al.
Publicado: (2021)

Experiences and Perceptions of Older Adults with Lower-Risk Hormone Receptor-Positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey
por: Savard, Marie-France, et al.
Publicado: (2021)

Regularly scheduled physical examinations and the detection of breast cancer recurrences
por: Beltran-Bless, Ana-Alicia, et al.
Publicado: (2023)

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014)

Management Strategies for Older Patients with Low-Risk Early-Stage Breast Cancer: A Physician Survey
por: Alzahrani, Mashari, et al.
Publicado: (2021)

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer
por: Awan, Arif, et al.
Publicado: (2020)

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events
por: Addison, Christina L., et al.
Publicado: (2014)

A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer
por: Fernandes, Ricardo, et al.
Publicado: (2023)

A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting
por: Clemons, M., et al.
Publicado: (2020)

Delivery of cancer care via an outpatient telephone support line: a cross-sectional study of oncology nursing perspectives on quality and challenges
por: Shah, Hely, et al.
Publicado: (2022)

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)
por: Hilton, John, et al.
Publicado: (2018)

Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial
por: Awan, Arif, et al.
Publicado: (2021)

A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia
por: Clemons, Mark, et al.
Publicado: (2021)

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

P291 Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers
por: Beltran-Bless, A.-A., et al.
Publicado: (2023)

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017)

Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers
por: Kuchuk, Iryna, et al.
Publicado: (2013)

P279 A patient survey evaluating COVID-19-induced changes in follow-up of patients with EBC: opportunities for enhanced evidence-based practice?
por: Beltran-Bless, A.-A., et al.
Publicado: (2023)

A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction
por: Arnaout, Angel, et al.
Publicado: (2020)

Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program
por: Alshamsan, Bader, et al.
Publicado: (2022)

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists
por: Hutton, Brian, et al.
Publicado: (2013)

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
por: Tu, Megan M., et al.
Publicado: (2021)

Can routinely collected administrative data effectively be used to evaluate and validate endpoints used in breast cancer clinical trials? Protocol for a scoping review of the literature
por: Shah, Hely, et al.
Publicado: (2023)

Optimising weight-loss interventions in cancer patients—A systematic review and network meta-analysis
por: LeVasseur, Nathalie, et al.
Publicado: (2021)

Young Women with Breast Cancer: The Current Role of Precision Oncology
por: Srikanthan, Amirrtha, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic
por: Tse, Tabitha, et al.
Publicado: (2021)

Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer
por: Zhao, Huijun, et al.
Publicado: (2023)

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review
por: Fernandes, Ricardo, et al.
Publicado: (2017)

Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges?
por: Gainford, M.C., et al.
Publicado: (2006)

Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective
por: McGee, Sharon F., et al.
Publicado: (2022)

Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?
por: Russell, Kent, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2vfrnt5709aiadgr4cjtllppn6